These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23924796)

  • 1. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
    Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
    MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
    Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
    Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
    Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
    Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
    J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
    Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
    MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
    Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
    Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.
    Lu D; Yadav R; Holder P; Chiang E; Sanjabi S; Poon V; Bernett M; Varma R; Liu K; Leung I; Bogaert L; Desjarlais J; Shivva V; Hosseini I; Ramanujan S
    Eur J Pharm Sci; 2023 Jul; 186():106450. PubMed ID: 37084985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
    Yan X; Mager DE; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
    Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
    J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
    Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.
    Charrin S; Le Naour F; Labas V; Billard M; Le Caer JP; Emile JF; Petit MA; Boucheix C; Rubinstein E
    Biochem J; 2003 Jul; 373(Pt 2):409-21. PubMed ID: 12708969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
    Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.